Difference between revisions of "Part:BBa K4156119"
 
(4 intermediate revisions by the same user not shown)
Line 10: Line 10:
  
 
The construction of this part is similar to XOR gate-mRFP (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156124"> BBa_K4156124 </a></html>). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.
 
The construction of this part is similar to XOR gate-mRFP (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156124"> BBa_K4156124 </a></html>). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.
 +
 +
===Characterization===
 +
 +
We used three different promoters in combination with XOR gate-HlyE to characterize the therapeutic efficacy of bacteria under the control of different promoters and TP901 coupled logic gates, and with the addition of lysis genes.
 +
 +
Characterization details can be found at：
 +
 +
pCadC-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156099"> BBa_K4156099 </a></html>
 +
 +
pCadC-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156100"> BBa_K4156100 </a></html>
 +
 +
pLldR-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156104"> BBa_K4156104 </a></html>
 +
 +
pLldR-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156105"> BBa_K4156105 </a></html>
 +
 +
pPepT-TP901:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156108"> BBa_K4156108 </a></html>
 +
 +
pPepT-TP901-φ174E:<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156109"> BBa_K4156109 </a></html>
 +
  
  

Latest revision as of 01:59, 12 October 2022


XOR gate-HlyE

XOR gate-HlyE consists of an XOR logic gate ( BBa_K4156117 ) and a downstream HlyE ( BBa_K4156084 ) sequence, and tests the performance of the XOR gate by detecting the red fluorescent signal.


Usage and Biology

The construction of this part is similar to XOR gate-mRFP ( BBa_K4156124 ). The difference is that we replaced the mRFP protein with the HlyE therapeutic protein. This is to verify the therapeutic power of the recombinant strain under XOR gate control. After co-incubation of the recombinant strain with cancer cells, cell viability was monitored using the CCK8 assay to assess the therapeutic power of the recombinant strain and the reinforcing effect of the XOR gate.

Characterization

We used three different promoters in combination with XOR gate-HlyE to characterize the therapeutic efficacy of bacteria under the control of different promoters and TP901 coupled logic gates, and with the addition of lysis genes.

Characterization details can be found at：

pCadC-TP901: BBa_K4156099

pCadC-TP901-φ174E: BBa_K4156100

pLldR-TP901: BBa_K4156104

pLldR-TP901-φ174E: BBa_K4156105

pPepT-TP901: BBa_K4156108

pPepT-TP901-φ174E: BBa_K4156109


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 614
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal NgoMIV site found at 104
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 124
    Illegal BsaI.rc site found at 351